Funded by the European Union
European Research Council (ERC)
Department / Institute: Institute of Pathology
Human Non neoplastic interstitial lung diseases are complex, ill understood and consist of >120 defined entities. During the first half of this projects, we were able to uncover important mechanistic pathways and characteristics of interstitial lung disease.
As the second wave of SARS-CoV-2 infections is emerging in Europe, more and more long-term consequences of COVID-19 pneumonia emerged, hinting at infection-induced interstitial lung diseases. The aim of this project is to translate our knowledge in non neoplastic interstitial lung diseases and acute SARS-CoV-2 induced pneumonia (Ackermann et al. 2020) ) onto COVID-19 and espcecially their potential long-time consequences.
Ackermann M, Verleden SE, Kuehnel M et al (2020) Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med.
Further Projects funded by the EU
Department / Institute: Institute of Transfusion Medicine and Transplant Engineering
COVID-19 convalescent plasma (CCP) donated by recovered patients is a promising treatment option for COVID-19 and is being used or trialled in more than half of EU Member States. This involves CCP being transfused to sick patients to boost their ability to fight the virus. Through its Emergency Support Instrument (ESI) the European Union provides a needs‐based, coordinated emergency response to help Member States address needs related to the immediate acute phase of the COVID-19 pandemic, as well as the exit, recovery and prevention of any resurgence. The objective of this project is to facilitate urgent and efficient increases in the capacity for collection, storage and testing of CCP for the treatment of COVID-19 patients to improve their health condition, reduce mortality and decrease time in hospital. The increased availability of CCP will also be exchanged within and between Member States to deal with localised shortages and spikes in COVID-19.